2024 May 08
1.
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis. Himmelbauer MK, Bajrami B, Santoro JC, Schulz J, Sciabola S, Tang H, Vandeveer HG, Wang T, Yousaf Z, Helal CJ, Hopkins BT.
J Med Chem. 2024 May 7. doi: 10.1021/acs.jmedchem.4c00220. Online ahead of print.
PMID: 38712838